New stroke drug in a hospital trial: more patients recovered fully at 90 days
☕ Includes a question for the family ↓
StrokePart of a story we are following · 7 articles · See every update
This is a hospital treatment, not something you can take at home. Still, it is real news for anyone who cares about stroke recovery. In a trial of 997 adults with acute ischemic stroke in China, 69.7% of those given the drug loberamisal reached a full functional outcome at 90 days, compared with 56.3% of those given a placebo.
In plain terms, more people in the drug group were back to little or no disability three months later. The drug was given on top of standard stroke care.
How the study worked
This was a phase 3 randomized trial, the kind of study that gives the clearest answers about whether a treatment works. It was double-blind, so neither patients nor doctors knew who got the drug and who got the look-alike placebo. It took place at 32 hospitals in China and was published on September 10, 2026 in JAMA. Because it only included adults aged 18 to 80 treated in China, more studies are needed to confirm the results and see whether they hold for a wider group of patients.
What did the loberamisal stroke trial find?
People in the study were adults with acute ischemic stroke who arrived within 48 hours of their first symptoms. None of them had a disability before the stroke. They were randomly split into two equal-sized groups. One group got an intravenous dose of loberamisal (40 mg) once a day for 10 days. The other got a matching placebo on the same schedule.
The main goal was a full functional outcome at 90 days. The scientists measured it with a standard disability scale and counted a score of 0 or 1 as a full outcome.
Here is how it came out:
| Loberamisal | Placebo | |
|---|---|---|
| People analyzed | 502 | 495 |
| Full functional outcome at 90 days | 350 people (69.7%) | 279 people (56.3%) |
That is a gap of about 13 percentage points. The exact figure from the study is 13.28%.
Was it safe?
The researchers also tracked side effects, and the two groups looked alike. Adverse events of any kind happened in 87.8% of the loberamisal group and 88.7% of the placebo group. Serious adverse events happened in 8.6% of the loberamisal group and 10.7% of the placebo group. Deaths from any cause were 1.2% in the loberamisal group and 2.0% in the placebo group.
The drug did not bring more side effects than the placebo in this trial. That is a useful thing to know about any new treatment.
Why does this matter if you can’t use it?
Effective treatments that protect and repair the brain after a stroke are still few. Loberamisal is a small molecule that acts on two targets in the brain, and this trial is a sign that this approach is worth following. It is one trial, and the authors say further studies are needed. Even so, it is a hopeful step for the people who recover from stroke and for their families.
What you can do today
Take two minutes to talk with someone you live with about what you would do if either of you suddenly showed signs of a stroke. Agree on the plan: call for emergency help right away and note the time the symptoms began. The people in this trial were treated within 48 hours of their first symptoms, so a clear plan ready ahead of time is a good thing to have.
Talk about it at home
To find out whether a new treatment really helps, scientists split the people in a study by chance, a bit like drawing names from a hat. Some got the real treatment and others got a look-alike that does nothing, and nobody knew who got which, not even the doctors. It works like a taste test with the labels covered: when nobody knows what is in the cup, nobody can be fooled by what they expect.
Try it at home
Look up together how the brain can build new paths around a spot that is not working well, a bit like a town finding a new road when a bridge is closed. Find out what scientists call this ability, and which everyday things, like learning a song or a new game, help the brain build new paths.
Keep exploring
Copies this article and its questions so you can paste them into ChatGPT, Claude, Gemini or the AI you use, and keep the conversation going.
Cite this article
Mongevity Desk. New stroke drug in a hospital trial: more patients recovered fully at 90 days. Mongevity. Published November 10, 2026. Accessed November 22, 2026. https://mongevity.science/heart/2026/11/loberamisal-stroke-trial-full-recovery/Mongevity Desk. New stroke drug in a hospital trial: more patients recovered fully at 90 days [Internet]. Mongevity; 2026 Nov 10 cited 2026 Nov 22]. Available from: https://mongevity.science/heart/2026/11/loberamisal-stroke-trial-full-recovery/Mongevity Desk. (2026, November 10). New stroke drug in a hospital trial: more patients recovered fully at 90 days. Mongevity. https://mongevity.science/heart/2026/11/loberamisal-stroke-trial-full-recovery/
<a href="https://mongevity.science/heart/2026/11/loberamisal-stroke-trial-full-recovery/">New stroke drug in a hospital trial: more patients recovered fully at 90 days</a>
Free to share or quote with credit and a link.
Questions and answers
- What is loberamisal?
- It is a small-molecule drug that acts on two targets in the brain. In this trial it was given through an IV in the hospital, once a day for 10 days.
- How many people were in the loberamisal trial?
- 998 adults were randomly assigned, and 997 received at least one dose and were analyzed. 502 got loberamisal and 495 got a placebo.
- How many people recovered fully with loberamisal?
- At 90 days, 69.7% of the loberamisal group had a full functional outcome, compared with 56.3% of the placebo group.
- Is loberamisal available to patients now?
- The study does not say. The authors note that further studies are needed to confirm the findings and see whether the benefits apply to a broader group of patients.





